Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T13:43:00.152Z.
Calculation as of: 2026-10-06T13:43:00.152Z.
Quote observation: 2026-10-06T13:40:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 84870b41b004d4a356f3546a7a12828ec10b1f950fc42869db9e2e4c5d55c05b
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$548.89M
EV/EBITDA Ratio
N/A
TTM Avg
144.36x
3Y Avg
144.36x
5Y Avg
144.36x
Market Cap
$552.97M
EV/EBITDA Ratio
N/A
TTM Avg
13.55x
3Y Avg
10.69x
5Y Avg
10.69x
Market Cap
$560.18M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$512.56M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | $540.75M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $538.28M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $548.89M | N/A | 144.36x | 144.36x | 144.36x |
| Crescent Biopharma, Inc. (CBIO)vs › | $532.27M | N/A | N/A | N/A | N/A |
| CytomX Therapeutics, Inc. (CTMX)vs › | $552.97M | N/A | 13.55x | 10.69x | 10.69x |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $560.18M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $518.76M | N/A | N/A | N/A | N/A |
| CorMedix Inc. (CRMD)vs › | $562.85M | 1.79x | 5.90x | 15.41x | 15.41x |
| Allogene Therapeutics, Inc. (ALLO)vs › | $512.56M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $570.87M | N/A | 42.12x | 42.12x | 42.12x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
